Phase II Study of Weekly Paclitaxel as Second-Line Therapy in Patients With Non-Small Cell Lung Cancer
OBJECTIVES: I. Determine the response rate and response duration in patients with recurrent
or refractory non-small cell lung cancer (NSCLC) treated with second line paclitaxel. II.
Determine the qualitative and quantitative toxicities of this treatment regimen in relapsed
patients with recurrent NSCLC. III. Evaluate the time to treatment failure and overall
survival in this patient population.
OUTLINE: Patients receive paclitaxel IV over 1 hour weekly for 6 weeks. Courses repeat every
8 weeks in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: Approximately 30-60 patients will be accrued for this study.
Primary Purpose: Treatment
Joan H. Schiller, MD
University of Wisconsin, Madison
United States: Federal Government
|University of Wisconsin Comprehensive Cancer Center||Madison, Wisconsin 53792|